PE-22-28

The downside is dominated by uncertainty rather than a documented catastrophe. PE-22-28 has no human safety signal because no human has ever been studied, which is its own kind of risk, and that blank is compounded by the biphasic-dosing trap and by off-target exposure in tissues that have nothing to do with mood. Cost and effort are typical grey-market peptide burdens, neither extreme on its own. Dependency is low and reversibility is mediocre, both inferred from the short rodent half-life rather than measured in a person. The heaviest weights come from safety, opportunity cost, and the practical effort of running an unvalidated injectable with no settled protocol. Worth saying plainly: the downside here is not that PE-22-28 has shown harm, it is that nobody has looked, and looking is the only thing that would tell us whether the off-target footprint and the dose-direction trap translate into real problems in people. Scoring an unknown as moderate rather than safe is the honest call, because absence of evidence is not evidence of safety.

Safety Risk (2.8/5.0): Safety risk is moderate, driven by unknowns rather than a confirmed catastrophic signal. There is no human safety data at all, no human pharmacokinetics, and no documented adverse-event profile, so everything here is theoretical or extrapolated from animals. Two concrete concerns stand out. The dose response is biphasic, where a low dose activates TREK-1 and a higher dose inhibits it, so a naive dose escalation can reverse the intended effect, per Djillani 2019. And TREK-1 is expressed well beyond the brain, including pancreatic beta cells where blockade acts as an insulin secretagogue in animals, per Hivelin 2016, plus heart, vasculature, and gut. None of that is a proven human harm, which is why the score is moderate rather than high, but the uncharacterized breadth on a multi-tissue target is exactly what makes self-injection a gamble.

Side Effect Profile (2.6/5.0): Side effects are moderate and almost entirely undocumented, because there is no human study to document them. In practice that means nobody can tell you what to expect, which is a downside in itself. The animal off-target work flags the likely watch areas: blood sugar shifts from the insulin-secretagogue effect, per Hivelin 2016, and theoretical cardiovascular effects from TREK-1 in heart and vascular tissue. Grey-market sourcing adds injection-site reactions, contamination, and dosing errors on top of the peptide itself. The score sits in the middle because absence of documented side effects is not the same as safety; it is just absence of data.

Financial Cost (3.0/5.0): Cost is moderate. Research-chemical peptides like this are not especially expensive per vial, and the dose is small, so the raw spend is manageable. What erodes the value is that you are paying for a compound with zero human proof, so even a modest cost buys an uncertain outcome. There is no pharmaceutical-grade option to pay up for, which keeps the price low but also means you cannot buy your way to verified quality. The score reflects a fair material cost paired with poor value given the evidence gap.

Time/Effort Burden (2.8/5.0): Effort is meaningful. PE-22-28 is an injectable that arrives as lyophilized powder, so it needs reconstitution with bacteriostatic water, subcutaneous injection, cold-chain storage, and careful handling of an unvalidated dose. The biphasic pharmacology makes the effort worse, because there is no settled protocol to follow and getting the dose direction right actually matters here. Compared with an oral supplement, that is a real daily logistics load, and the lack of any reference dose means more guesswork than a typical peptide. The score reflects standard injectable friction plus the extra cognitive load of an undefined dose.

Opportunity Cost (3.0/5.0): Opportunity cost is genuine, because better-supported options exist for the same goals. If the aim is mood, focus, or neuroprotection, peptides like Semax and Bromantane at least have human use behind them, and Dihexa sits in the same preclinical neuro-peptide space for comparison. Money, effort, and self-experimentation risk spent on a compound with zero human data could go toward those, or toward the sleep, training, and stress basics that move mood with far more certainty. The score reflects a real and avoidable trade-off rather than a forced choice.

Dependency/Withdrawal (1.8/5.0): Dependency risk is low, inferred from the pharmacology rather than measured. PE-22-28 is not known to suppress a hormonal axis or to act on classic reward circuits, and its short rodent half-life means it clears quickly, so functional reliance would mean simply losing a benefit when you stop rather than experiencing withdrawal. There is no documented addiction or withdrawal syndrome in any species. The score is low because the mechanism does not predict dependence, with the honest caveat that no human has been observed over time, so this is a reasonable inference, not a guarantee.

Reversibility (2.0/5.0): Reversibility is mediocre and, like everything here, unstudied in humans. The short rodent half-life suggests acute effects wash out within roughly a day, which mildly favors reversibility for a bad reaction. But the neurogenesis and synaptogenesis effects in animals raise the possibility of structural changes that would not reverse on the same timescale, and there is no human washout, tolerance, or long-term follow-up data to confirm either way. On a multi-tissue target with no human safety profile, an effect you cannot quickly undo is a real concern, so the score lands below the midpoint.

The design thesis is also the dosing trap: a low dose of a spadin-class peptide activates TREK-1 for neuroprotection while a higher dose inhibits it for the antidepressant effect, so assuming more is better can flip the result you are chasing.Djillani 2019, Neuropharmacology